|January '02 | briefing | mail | don't say this | flakers' jargon | flaker creativity | articles | other places | archives | send mail | ed dewke | legal stuff | order | search | ©2001 Ed Dewke|
Joint Pain After Anti-CD11a Trial
I find your website very interesting and informative.
I am 33 and have had psoriasis for over 10 years now.
It has been severe for the past 2 years.
I did the anti-cd11a study last year and was one of the few that
saw no improvement at all. It
surprised the doctor overseeing the study.
I started to develop joint pain during the study.
In the last month it began to get severe and then in the month
after, the pain was all over my body and I was unable to walk.
I missed more than a month of
work, but thanks to a great doctor and the medication I am on, I am
feeling much better. Of
course, now I will always have to deal with the psoriatic arthritis.
I am very concerned that the
study drug, anti-cd11a, led to my current condition.
I am concerned that it could happen to other people.
The psoriasis I have is nothing in comparison to the horrific pain
I endured just a few months ago. The
swelling and pain were unbearable!
I would like to chat with anyone
who experienced any type of pain while on the anti-cd11a drug study.
It is very important to me to hear from anyone who had any joint
pain during or after the study. I
think that Genentech knows more about this problem than they are telling
study participants. It would
be greatly appreciated if you could get the word out to others.
You have my permission to post this with my email address.
Thanks! –Lesleigh ([email protected])
Your email was propitiously timed, Lesleigh.
In the November/December issue of the NPF
Bulletin, this item: “Genentech, which is moving toward FDA
approval for its psoriasis treatment efalizumab (brand name Xanelim) was
the first biotechnology company” (page 9, sidebar to “The research
pipeline for psoriasis”). Xanelim is the drug growing out of the
anti-CD11a trials. The
importance of Genentech being the “first biotechnology company,” is
the way this differentiates them from traditional pharmaceutical
companies. In the sidebar from
which I drew the quote, it is explained that traditional drugs involve
non-living chemicals but new “biologic drugs” involve living sources
“such as viruses, animals and people.”
In an earlier report on
Genentech’s research (also at NPF’s web site), I read that during
their Phase III trial they used 950 test subjects.
You, evidently, were among them.
Also from this report: “[A]nti-cd11a, a humanized monoclonal
antibody that is being developed by Genentech and XOMA … blocks the
movement of immune system cells (called T cells) from the bloodstream into
the skin and the activation of those cells within the skin. T-cell
activation is a critical step in the misfired immune response that results
While we all want Xanelim to
become an important break-through treatment for P, there is no such thing
as an unimportant adverse reaction, which you have experienced
dramatically. I hope any
readers who participated in the trial and have experienced similar
reactions will let us know as well as contact you directly.
Thanks for your report, Lesleigh.